beat · 27 stories
A 32-patient postmortem study compared a leading Alzheimer's blood test with brain tissue from the same donors. The blood marker, a tau fragment called pTau217, tracked 0.73–0.78 against the cortex.
The workplan schedules finalization of the January 2025 AI lifecycle draft and the change-control framework that lets adaptive medical models update after approval. Comments close 30 November.
The $1 billion Cambridge building opens with 10 floors of interconnecting labs and a 1,100-employee launch roster, slotting next to AZ's existing 100 Binney genomic-medicine footprint.
The FDA is soliciting public comment on cardiac monitoring, dosing limits, and trial-stopping rules for the first federal ibogaine research program, a $50M initiative born from an April executive order.
In-Q-Tel, the BioNTech co-founder's family office, and the Slovak government are betting on a startup that wants to replace 40-year-old mRNA chemistry with engineered cells.
A University of Sydney team built a gene-expression benchmark for lab-grown embryo models, finding each of the four leading methods captures part of real human development but none yet match it fully.
The trigger is a viral protease, an enzyme the virus uses to assemble itself, that also cuts a bacterial sensor and flips on CBASS, one of the most common antiviral defenses.
A study in the journal *Brain* validates a long-studied inflammation target in real human brain tissue, opening a path to repurpose existing drug candidates against TBI and Alzheimer's.
A Cornell team found BC200, a gene that helps neurons build proteins, never stopped moving through DNA, and two copies of it ended up inside a human poxvirus.
The framework ranked prompt-defined competence on synthetic MI (motivational interviewing) and CBT (cognitive behavioral therapy) sessions. The open test is real trainees and item-level fidelity benchmarks.
The 31-valent shot met its primary endpoints, with strain coverage well beyond Pfizer's Prevnar 20 and Merck's Capvaxive, the two current adult pneumonia vaccines, but two more trials still gate an FDA filing.
Nolla Health will assess Utah patients for mild-to-moderate acne and write a low-risk prescription, with a clinician signing off in the first phase and a path to unsupervised prescribing under the state AI sandbox.